An observational study in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-10-30.
Sponsored by AstraZeneca · Observational
The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus
This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 653 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Type 2 Diabetes patients with administrative claims data from Optum Research Database (US Commercial Claims Data)
Exclusion Criteria:
Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
Condition-specific treatment satisfaction
Condition-specific treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: 2 weeks
Medical Outcomes Study (MOS) Short Form Health Survey SF-12 or SF-36
MOS Short Form Health Survey SF-12 or SF-36
Time frame: 4 weeks
Morisky Medication Adherence Scale
Medication adherence
Time frame: 1 month
Hypoglycemia Fear Survey
Fear of hypoglycemia (HFS)
Time frame: 4 weeks
Self-reported body weight
Self-reported body weight
Time frame: 1 month
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca